
    
      Patients who meet criteria for participation in this study receive 8 intravenous infusions of
      MabionCD20® or MabThera® 21 days interval in combination with standard dosage regimen of
      CHOP. The duration of the study is 12 months. The treatment and observation period will last
      26 weeks starting from Day 1, until Week 26 - one month after last IMP infusion.
    
  